Organovo Partners With IIAM on Multi-Year Clinical Biomaterial Sourcing Agreement
November 12, 2018 08:05 ET
|
Organovo, Inc.; International Institute for the Advancement of Medicine (“IIAM”)
SAN DIEGO, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range...
Organovo Affirms Key Clinical Development Goals; Company Reports Fiscal Second-Quarter 2019 Results
November 08, 2018 16:05 ET
|
Organovo, Inc.
Pre-Investigational New Drug (“IND”) meeting with the FDA expected to be held in calendar 2019Second orphan designation anticipated in first half of calendar 2019Submit first IND in calendar 2020 ...
Organovo Announces Release Date for Fiscal Second-Quarter 2019 Financial Results
October 18, 2018 08:05 ET
|
Organovo, Inc.
SAN DIEGO, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) will host a conference call on Thursday, November 8, 2018 at 5:00 p.m. Eastern Time (ET) to discuss...
Organovo to Present New Preclinical Data on 3D Bioprinted Human Liver Tissues for the Treatment of Tyrosinemia I at the Liver Meeting® 2018 (AASLD)
October 15, 2018 08:05 ET
|
Organovo, Inc.
SAN DIEGO, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range...
Organovo to Present at 2018 Cell & Gene Meeting on the Mesa
September 26, 2018 08:05 ET
|
Organovo, Inc.
SAN DIEGO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a...
Organovo Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 14, 2018 17:00 ET
|
Organovo, Inc.
SAN DIEGO, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo” or the “Company”) announced the grant of inducement awards on August 14, 2018 to Dr. Steven G. Hughes,...
Organovo Reports Fiscal First-Quarter 2019 Results; Company Outlines and Expands Key Clinical Development Goals
August 09, 2018 16:05 ET
|
Organovo, Inc.
Pre-Investigational New Drug (“IND”) meeting with the FDA expected to be held in calendar 2019 Lead IND program for Alpha-1-antitrypsin deficiency (“A1AT”) expected to commence IND-enabling...
Organovo Announces Appointment of Steven G. Hughes, M.D. as Chief Medical Officer
August 01, 2018 08:05 ET
|
Organovo, Inc.
SAN DIEGO, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) today announced that Steven G. Hughes has been named Chief Medical Officer. Dr. Hughes is an industry...
Organovo Announces Release Date for Fiscal First-Quarter 2019 Financial Results
July 19, 2018 08:05 ET
|
Organovo, Inc.
SAN DIEGO, July 19, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) will host a conference call on Thursday, August 9, 2018 at 5:00 p.m. Eastern Time (ET) to discuss the...
Organovo Reports Fiscal Fourth-Quarter and Full-Year 2018 Results; Company Announces Key Goals for Fiscal-Year 2019
May 31, 2018 16:05 ET
|
Organovo, Inc.
- Lead Investigational New Drug (“IND”) program for Alpha-1-antitrypsin deficiency (“A1AT”) received FDA’s orphan drug designation and is on track for commencing IND-enabling studies in fiscal 2019 -...